Rosiglitazone reduced type 2 diabetes but increased heart failure in patients with impaired glycemic control

Gandhi, Gunjan Y.; Swiglo, Brian A.
January 2007
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p8
Academic Journal
The article cites a study regarding the effectiveness of rosiglitazone for the treatment of type 2 diabetes in patients with impaired glucose tolerance. The study was conducted by researcher H.C. Gerstein and colleagues, and published in the journal "The Lancet." There were few patients with outcome of diabetes, who received rosiglitazone than patients receiving placebo. The incidence of heart failure increased by this method.


Related Articles

  • Beating the sugar blues with nature.  // Food & Drink Technology;Mar2007, Vol. 6 Issue 6, p14 

    The article provides information about the efficiency of Chromium Picolinate used in improving the condition of type 2 diabetes patients in Great Britain. It has been stated that diabetes affects the stability of the body's insulin response and several million people in the country will become...

  • Time for Clinically Relevant Comparative Effectiveness Studies in Type 2 Diabetes. Nathan, David M. // Annals of Internal Medicine;1/18/2011, Vol. 154 Issue 2, p131 

    The author reflects on the study that aims to compare the effectiveness of exenatide and placebo in decreasing the levels of blood sugar in patients with type 2 diabetes. He emphasizes that the study is not adequate for comparing the effectiveness and cost effectiveness of the medications at...

  • PhaseBio Pharmaceuticals Initiates a Multicenter, Randomized Placebo and Active.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article presents information on an announcement made by PhaseBio Pharmaceuticals Inc. regarding commencement of a multicenter, randomized placebo and active comparator controlled Phase 2b trial for the evaluation of the use of drug Glymera to treat uncontrolled type 2 diabetes. The study...

  • The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy. Fouqueray, Pascale; Pirags, Valdis; Diamant, Michaela; Schernthaner, Guntram; Lebovitz, Harold E.; Inzucchi, Silvio E.; Bailey, Clifford J. // Diabetes Care;Jul2014, Vol. 37 Issue 7, p1924 

    OBJECTIVE This 12-week study assessed the efficacy and tolerability of imeglimin as add-on therapy to the dipeptidyl peptidase-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. RESEARCH DESIGN AND METHODS In a multicenter, randomized,...

  • American Diabetes Association.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p9 

    The article discusses the results reported by Bristol-Myers Squibb Co. and AstraZeneca plc from an interim analysis of a long-term phase III study that examined the effectiveness of Onglyza or saxagliptin, a DPP-4 inhibitor, when combined with metformin for people with inadequately controlled...

  • Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Tang, Wen-Hao; Lin, Fu-Huang; Lee, Chien-Hsing; Kuo, Feng-Chih; Hsieh, Chang-Hsun; Hsiao, Fone-Ching; Hung, Yi-Jen // Endocrine (1355008X);Mar2014, Vol. 45 Issue 2, p293 

    Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties. To date, no clinical study has specifically evaluated the efficacy of cilostazol in patients with diabetic nephropathy (DN). We hypothesized that cilostazol might delay renal deterioration in DN patients at...

  • Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. Rosenstock, Julio; Vico, Marisa; Li Wei; Salsali, Afshin; List, James F. // Diabetes Care;Jul2012, Vol. 35 Issue 7, p1473 

    OBJECTIVE--To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone. RESEARCH DESIGN AND METHODS--Treatment-naive patients or those receiving metformin, sulfonylurea, or...

  • Exploratory Trial of Intranasal Administration of Glucagon-Like Peptide-1 in Japanese Patients With Type 2 Diabetes. Hiroaki Ueno; Masanari Mizuta; Tomomi Shiiya; Wakaba Tsuchimochi; Kenji Noma; Noboru Nakashima; Mitsuteru Fujihara; Masamitsu Nakazato // Diabetes Care;Jul2014, Vol. 37 Issue 7, p2024 

    OBJECTIVE This study aimed to assess the efficacy and safety of our newly developed nasal glucagon-like peptide-1 (GLP-1) compound and injector. RESEARCH DESIGN AND METHODS Twenty-six patients with type 2 diabetes were enrolled in this double-blind placebo-controlled study. The nasal compound...

  • Efficacy and Safety of Oral Methazolamide in Patients With Type 2 Diabetes: A 24-Week, Placebo-Controlled, Double-Blind Study. Simpson, Richard W.; Nicholson, Geoffrey C.; Proietto, Joseph; Sarah, Alana; Sanders, Kerrie M.; Phillips, Gabrielle; Chambers, Jo; MacGinley, Rob; Orford, Neil; Walder, Ken; Krippner, Guy; Skoff, Kathy; Wacher, Vincent J. // Diabetes Care;Nov2014, Vol. 37 Issue 11, p3121 

    OBJECTIVE To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes. RESEARCH DESIGN AND METHODS This double-blind, placebo-controlled study randomized 76 patients to oral methazolamide (40 mg b.i.d.) or placebo for 24 weeks. The primary efficacy end point...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics